Last edition
News about "CEO Albert Bourla"
Pfizer Raises 2025 Profit Forecast After Strong Q2; Adjusted EPS Seen at USD 2.90-3.10
Pfizer has raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 2.90–3.10, up from its prior outlook of USD 2.80–3.00, following strong second-quarter results that beat market expectations.
CEO Albert Bourla | 06/08/2025 | By Darshana | 203
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members